Abstract
Selective accumulation of an exogenous enzyme or activating agent at a target cell allows use of prodrugs that will be unmasked only at this site. This can reduce the side effects of chemotherapy and allow more potent drugs to be used in various treatments. Examples of this two-step prodrug therapy include antibody- (ADEPT, ADAPT), genetic- (GDEPT, VDEPT) and macromolecule-based approaches (PDEPT, LEAPT). Carbohydrate chemistry and glycobiology feature in each of these areas and is the focus of this review.
Keywords: Abzymes, antibodies, asialoglycoprotein receptor, daunorubicin, doxorubicin, glycoconjugates, glycosidases, HPMA, prodrugs
Current Drug Delivery
Title: Painting the Target Around the Arrow: Two-Step Prodrug Therapies from a Carbohydrate Chemists Perspective
Volume: 4 Issue: 4
Author(s): Todd A. Houston
Affiliation:
Keywords: Abzymes, antibodies, asialoglycoprotein receptor, daunorubicin, doxorubicin, glycoconjugates, glycosidases, HPMA, prodrugs
Abstract: Selective accumulation of an exogenous enzyme or activating agent at a target cell allows use of prodrugs that will be unmasked only at this site. This can reduce the side effects of chemotherapy and allow more potent drugs to be used in various treatments. Examples of this two-step prodrug therapy include antibody- (ADEPT, ADAPT), genetic- (GDEPT, VDEPT) and macromolecule-based approaches (PDEPT, LEAPT). Carbohydrate chemistry and glycobiology feature in each of these areas and is the focus of this review.
Export Options
About this article
Cite this article as:
Houston A. Todd, Painting the Target Around the Arrow: Two-Step Prodrug Therapies from a Carbohydrate Chemists Perspective, Current Drug Delivery 2007; 4 (4) . https://dx.doi.org/10.2174/156720107782151278
DOI https://dx.doi.org/10.2174/156720107782151278 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clinical Molecular Imaging with PET Agents Other than 18F-FDG
Current Pharmaceutical Biotechnology Improvements in Algorithms for Phenotype Inference: The NAT2 Example
Current Drug Metabolism The Potential Anti-Tumorigenic and Anti-Metastatic Side of the Proprotein Convertases Inhibitors
Recent Patents on Anti-Cancer Drug Discovery The Significance of Ubiquitin Proteasome Pathway in Cancer Development
Recent Patents on Anti-Cancer Drug Discovery Hereditary Papillary Renal Carcinoma Type I
Current Molecular Medicine Combining Gene Therapy and Radiation Against Cancer
Current Gene Therapy The Protective Action of the Aqueous Extract of Auricularia polytricha in Paracetamol Induced Hepatotoxicity in Rats
Recent Patents on Drug Delivery & Formulation The MYC Oncogene as a Cancer Drug Target
Current Cancer Drug Targets iHyd-PseAAC (EPSV): Identifying Hydroxylation Sites in Proteins by Extracting Enhanced Position and Sequence Variant Feature via Chou's 5- Step Rule and General Pseudo Amino Acid Composition
Current Genomics In Silico Prediction of P-glycoprotein Binding: Insights from Molecular Docking Studies
Current Medicinal Chemistry Immunomodulatory Activity of Astragalus, Ginseng and Echinacea: From Keith Block and Mark Mead to Today, Have We Moved On?
Current Immunology Reviews (Discontinued) Potential Targets for Intervention in Radiation-Induced Heart Disease
Current Drug Targets Effect of Curcumin on Pro-angiogenic Factors in the Xenograft Model of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Design, Synthesis, and Evaluation of (2-(Pyridinyl)methylene)-1-tetralone Chalcones for Anticancer and Antimicrobial Activity
Medicinal Chemistry Towards Liver-Directed Gene Therapy for Crigler-Najjar Syndrome
Current Gene Therapy The Antioxidants and Pro-Antioxidants Network: An Overview
Current Pharmaceutical Design MicroRNA-21: From Cancer to Cardiovascular Disease
Current Drug Targets Anticancer Drug Design Using Scaffolds of β-Lactams, Sulfonamides, Quinoline, Quinoxaline and Natural Products. Drugs Advances in Clinical Trials
Current Medicinal Chemistry Oral and Dental Considerations in the Management of Leukemic Children
Applied Clinical Research, Clinical Trials and Regulatory Affairs Targeted Drug Delivery Systems for Lung Macrophages
Current Drug Targets